LRRK2-IN-7

CAS No. 2307277-93-4

LRRK2-IN-7( —— )

Catalog No. M36503 CAS No. 2307277-93-4

LRRK2-IN-7 is a selective, CNS permeable and potent LRRK2 kinase inhibitor (IC50: 0.9 nM) for the study of Parkinson's disease.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 363 Get Quote
5MG 566 Get Quote
10MG 905 Get Quote
25MG 1398 Get Quote
50MG 1822 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    LRRK2-IN-7
  • Note
    Research use only, not for human use.
  • Brief Description
    LRRK2-IN-7 is a selective, CNS permeable and potent LRRK2 kinase inhibitor (IC50: 0.9 nM) for the study of Parkinson's disease.
  • Description
    LRRK2-IN-7 is a potent, selective, and CNS-penetrant LRRK2 kinase?inhibitor with an IC50 of 0.9 nM. LRRK2-IN-7 shows >1000-fold selectivity over other kinases, ion channels, and CYP enzymes.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Autophagy
  • Target
    LRRK2
  • Recptor
    LRRK2
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2307277-93-4
  • Formula Weight
    414.5
  • Molecular Formula
    C24H26N6O
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (241.25 mM; Ultrasonic )
  • SMILES
    C(#N)[C@@]1(C2(C1)CC2)C=3C=C4N(N=CC4=CC3)C=5C=C(N=CN5)N6C[C@H](C(C)(C)O)CC6
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. David A Candito, et al. Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1 H-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson's Disease. J Med Chem. 2022 Dec 22;65(24):16801-16817. ?
molnova catalog
related products
  • SCH 23390 hydrochlor...

    SCH 23390 hydrochloride is an effective dopamine receptor antagonist, and for the D1(Ki=0.2 nM) and D5(Ki=0.3 nM).

  • LRRK2-IN-7

    LRRK2-IN-7 is a selective, CNS permeable and potent LRRK2 kinase inhibitor (IC50: 0.9 nM) for the study of Parkinson's disease.

  • CZC-25146 hydrochlor...

    CZC-25146 is a selective LRRK2 inhibitor with IC50 of 4.76 nM/6.87 nM for wild type LRRK2 and G2019S LRRK2 respectively.